A Phase II Study of an Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
Latest Information Update: 14 Sep 2023
At a glance
- Drugs Alectinib (Primary) ; Cabozantinib (Primary) ; Crizotinib (Primary) ; Dabrafenib (Primary) ; Erlotinib (Primary) ; Imatinib (Primary) ; Nivolumab (Primary) ; Olaparib (Primary) ; Osimertinib (Primary) ; Palbociclib (Primary) ; Pembrolizumab (Primary) ; Sunitinib (Primary) ; Trametinib (Primary) ; Trastuzumab emtansine (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms INDIGO
Most Recent Events
- 21 Jan 2020 New trial record